Tevogen Bio Holdings Inc. (TVGN) - Dilution Analysis

10-Q filing | 4.2M shares outstanding

8-K filing: Stock split 1-for-50 | Outstanding: 196,028,784 → 3,920,575

10-Q filing | 196.0M shares outstanding

10-Q filing | 184.3M shares outstanding

8-K filing: As a result of restricted stock award grants approved by the Board of Directors on June 27, 2025, including a grant of 8,000,000 shares of restricted stock to the Company's CEO, the number of shares of the Company's common stock outstanding is 193,693,433.

S-3 filing: TEVOGEN BIO HOLDINGS INC. is filing an S-3 form to offer and sell from time to time up to $150,000,000 of any combination of common stock, preferred stock, depositary shares, debt securities, and purchase contracts, as well as the offering and potential resale by selling stockholders of up to 30,728,804 shares of common stock.

10-Q filing | 183.9M shares outstanding

POS AM filing: This prospectus relates to the issuance by us of up to (i) 17,974,000 shares of Common Stock upon the exercise of the Warrants originally issued by Semper Paratus as part of Semper Paratus' (a) initial public offering and (b) Private Placement of units at a price of $10.00 per unit, with each unit consisting of one Class A ordinary share of Semper Paratus and one-half of a warrant and (ii) 24,500,000 shares of Common Stock issuable upon the achievement of certain earnout triggering events, as described in the prospectus contained herein.

10-K filing | 183.9M shares outstanding

10-Q filing | 170.2M shares outstanding

8-K filing: Tevogen Bio Holdings Inc. entered into a securities purchase agreement with an investor for the purchase of 600 shares of Series C Preferred Stock for $6.0 million, and filed the Certificate of Designation of Series C Preferred Stock. ($6.0M proceeds)

10-Q filing | 154.2M shares outstanding

S-1/A filing: This S-1/A filing relates to the issuance of common stock upon exercise of warrants and achievement of earnout triggering events, as well as the resale of common stock and warrants by registered holders.

S-1/A filing: Tevogen Bio Holdings Inc. is filing an S-1/A form to register (i) 17,974,978 shares of common stock upon the exercise of outstanding warrants, (ii) 24,500,000 shares of common stock issuable upon the achievement of certain earnout triggering events, as well as the resale of (i) 24,851,308 shares of common stock and (ii) 725,000 warrants by the registered holders.

S-1 filing: This S-1 filing includes the registration of shares of common stock and warrants for issuance upon exercise and resale by registered holders, related to warrants, earnout provisions, and previous agreements.

8-K filing: Tevogen Bio Holdings Inc. entered into a Loan Agreement with The Patel Family, LLP, which includes a line of credit facility of up to $36.0 million and an option for the lender to purchase at least $14.0 million of the company's common stock in a future private placement; additionally, the company issued 1,000,000 shares of common stock to the lender as a commitment fee.

10-Q filing | 166.1M shares outstanding

8-K filing: Tevogen Bio Holdings Inc. entered into a binding term sheet with The Patel Family, LLP for an unsecured line of credit facility of up to $36.0 million and a contingent option for the Lender to purchase at least $14.0 million of the Company's common stock in a future private placement.

10-K filing | 164.6M shares outstanding

8-K filing: The Company sold 600 shares of Series A-1 Preferred Stock for $6.0 million. Each share of Series A-1 Preferred Stock is convertible into 1,000 shares of common stock, at the election of the holder. ($6.0M proceeds)

8-K filing: Tevogen Bio Holdings, Inc. filed the Certificate of Designation of Series A Preferred Stock and Series B Preferred Stock, creating the respective preferred stock series and establishing their rights, preferences, and terms. ($11.6M proceeds)

8-K filing: Tevogen Bio consummated a business combination on February 14, 2024, which involved unregistered sales of equity securities, including the issuance of 151,000 shares of Common Stock to Polar, 500,000 shares to Cantor, and 10,337,419 shares upon conversion of Assumed Notes. ($0.15M proceeds)

8-K filing: Semper Paratus Acquisition Corporation amended its Amended and Restated Memorandum and Articles of Association to extend the date by which it must complete its initial business combination to September 15, 2024, with SSVK Associates, LLC depositing funds into the Trust Account for each extension, and holders of 880,873 Class A ordinary shares exercised the right to redeem such shares for cash at an approximate price of $11.02 per share. ($9.7M proceeds)

10-Q filing | 15.8M shares outstanding

10-Q filing | 15.8M shares outstanding

8-K filing: Semper Paratus Acquisition Corporation entered into a Merger Agreement with Tevogen Bio Inc, where Tevogen Bio's capital stock will be exchanged for shares of Semper Paratus Class A common stock, with an aggregate value of $1,200,000,000, plus a potential additional 20,000,000 shares of Semper Paratus' Class A common stock upon achieving certain stock price targets.

8-K filing: New Sponsor, SSVK Associates, LLC, agreed to purchase from the Original Sponsor 7,988,889 Class A ordinary shares and 1,000,000 private placement units for an aggregate purchase price of $1.00 payable upon completion of the Initial Business Combination. ($0.0M proceeds)

10-Q filing | 13.4M shares outstanding

8-K filing: Semper Paratus Acquisition Corporation entered into a subscription agreement with Polar Multi-Strategy Master Fund for the issuance of 151,000 Class A ordinary shares and a purchase agreement with SSVK Associates, LLC for the sale of 7,988,889 Class A Ordinary Shares and 1,000,000 private placement units. ($0.0M proceeds)

10-K filing | 1.5M shares outstanding

8-K filing: On January 30, 2023, shareholders converted 11,983,333 Class B ordinary shares into 11,983,333 Class A ordinary shares, resulting in the Company having 47,933,333 Class A Shares issued and outstanding and no Class B ordinary shares issued and outstanding.

10-Q filing | 12.0M shares outstanding

10-Q filing | 12.0M shares outstanding

10-Q filing | 1.5M shares outstanding

10-K filing | 1.5M shares outstanding

10-Q filing | 12.0M shares outstanding

8-K filing: Semper Paratus Acquisition Corporation consummated its initial public offering of 34,500,000 units at $10.00 per Unit, generating gross proceeds of $345,000,000, and completed a private sale of 1,450,000 units at $10.00 per Private Unit, generating gross proceeds of $14,500,000. ($722.0M proceeds)

8-K filing: Semper Paratus Acquisition Corporation consummated its initial public offering of 34,500,000 units at $10.00 per unit, generating gross proceeds of $345,000,000. The company also completed private sales of 1,300,000 units to the Sponsor and 150,000 units to Cantor at $10.00 per unit, generating gross proceeds of $13,000,000 and $1,500,000, respectively. ($359.5M proceeds)

S-1/A filing: This S-1/A filing includes information about other expenses of issuance and distribution, indemnification of directors and officers, recent sales of unregistered securities, and exhibits.

S-1/A filing: This S-1/A filing details expenses, indemnification of directors and officers, recent sales of unregistered securities, and exhibits related to the offering.

S-1/A filing: This is an S-1/A filing providing information on expenses, indemnification, recent sales of unregistered securities, and exhibits.

S-1/A filing: Initial public offering of 30,000,000 units at $10.00 per unit, each unit consists of one Class A ordinary share and one-half of one redeemable warrant.

S-1 filing: Semper Paratus Acquisition Corporation is offering 30,000,000 units at $10.00 per unit, with each unit consisting of one Class A ordinary share and one-half of one redeemable warrant, in an initial public offering.